[Liposomes: promising perspectives].
NEW THERAPEUTIC VECTORS: Liposomes are nontoxic biodegradable lipid particles which can vehicle drug compounds to the site of action, thus limiting the risk of general toxicity. WITH AMINOGLYCOSIDES: Liposome vectors for aminoglycosides, particularly amikacin, have been developed. Oto- and hepatic toxicity can be limited allowing the use of higher doses for longer periods. WITH AMPHOTERICIN B: Liposomal amphotericin B is now available and appears to give interesting results both in terms of efficacy and tolerance. OTHER APPLICATIONS: Capsular forms of other antibiotics such as ciprofloxacin are being studied. An encapsulated anticytomegalovirus agent, foscamet, is also be explored. In cancerology, liposomes could be developed to deliver toxic agents such as doxorubicin for example. The high cost of these therapeutic vectors does however limit their current use.
Bricaire
F
F
D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004337:Drug Carriers; D005544:Forecasting; D006801:Humans; D008081:Liposomes / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies
D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B